Sionna Therapeutics, Inc. SION NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

40/100

1/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Sionna Therapeutics, Inc. (SION) has a negative trailing P/E of -19.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -5.02%.

Criteria proven by this page:

VALUE (32/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -19.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -5.02%).
Trailing Earnings Yield -5.02% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $46.25 (+2.6% upside) — modest upside expected.

Overall SharesGrow Score: 39/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

40/100

SG Score

View full scorecard →

✗

VALUE

32/100

Price-to-Earnings & upside

Proven by this page

FUTURE

55/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

40/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — SION

Valuation Multiples

P/E (TTM)-19.9

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio4.89

P/S Ratio0.00

EV/EBITDA-21.8

Per Share Data

EPS (TTM)$-1.88

Book Value / Share$7.68

Revenue / Share$0.00

FCF / Share$-1.67

Yields & Fair Value

Earnings Yield-5.02%

Dividend Yield0.00%

Analyst Target$46.25 (+2.6%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	Dividend Yield
2022	-27.4	0.00	-15.78	-
2023	-23.3	-1.34	-9.60	-
2024	-17.9	-0.58	-6.74	-
2025	-21.8	-0.64	5.36	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2022	$-2.32	$0.00	$-40.24M	-
2023	$-1.70	$0.00	$-47.26M	-
2024	$-15.99	$0.00	$-61.69M	-
2025	$-1.88	$0.00	$-75.27M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-2.33	$-3.07 – $-1.61	$0.00	$0.00 – $0.00	6
2027	$-2.60	$-3.57 – $-1.61	$3.75M	$3.75M – $3.75M	5
2028	$-2.89	$-3.79 – $-1.61	$4.29M	$4.29M – $4.29M	7
2029	$-2.58	$-2.58 – $-2.58	$32.6M	$32.6M – $32.6M	2
2030	$-2.32	$-2.32 – $-2.32	$75.77M	$75.77M – $75.77M	5